Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday

Key Points

• Phathom Pharmaceuticals is expected to report Q3 2026 results before the market opens on October 29, with analysts forecasting earnings of $0.07 per share and revenue of $84.82 million.
• PHAT shares opened at $7.03, near their 52-week low of $6.52 and below both the 50-day and 200-day moving averages.
• Analyst sentiment remains a Moderate Buy, with an average price target of $20.11, although several firms recently lowered their targets and one analyst maintains a sell rating.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.07 per share and revenue of $84.82 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Price Performance

Phathom Pharmaceuticals stock opened at $7.03 on Thursday. The stock has a fifty day moving average of $8.08 and a two-hundred day moving average of $10.03. Phathom Pharmaceuticals has a fifty-two week low of $6.52 and a fifty-two week high of $18.31.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PHAT. Weiss Ratings reiterated a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a report on Thursday, October 15th. Jefferies Financial Group restated a "buy" rating and set a $16.00 price target on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 14th. Needham & Company LLC dropped their price objective on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Guggenheim lowered their target price on Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, July 31st. Finally, Barclays lowered their price target on shares of Phathom Pharmaceuticals from $18.00 to $14.00 and set an "overweight" rating for the company in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $20.11.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company's portfolio is centered on vonoprazan, a potassium-competitive acid blocker designed to suppress gastric acid production and provide an alternative to traditional proton pump inhibitors.

Phathom markets vonoprazan in the United States under the brand name Voquezna. The product is approved for the healing and maintenance of healing of erosive esophagitis, relief of associated heartburn, and treatment of heartburn related to non-erosive gastroesophageal reflux disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.